Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 5/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608858 | 0.93 | BCAT2 (0.61) | BCAT2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL466296 | 0.90 | KDM4E (0.54) | BCAT2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL901580 | 0.88 | BCAT2 (0.71) | BCAT2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL31194394 | 0.88 | BCAT2 (0.55) | BCAT2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL3453140 | 0.88 | KDM4E (0.61) | BCAT2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL8675281 | 0.86 | KEAP1 (0.56) | BCAT2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL5742619 | 0.86 | MYC (0.53) | BCAT2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL5791257 | 0.86 | BCAT2 (0.44) | BCAT2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL8910680 | 0.84 | KDM4E (0.51) | BCAT2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL28442421 | 0.83 | SLC6A2 (0.46) | BCAT2KEAP1NFE2L2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295402-B1 | Antibacterial agents | UNIV WASHINGTON (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1618087-B1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2012040853-A1 | GROUP 5 METAL COMPLEXES USEFUL FOR AMINE FUNCTIONALIZATION AND SYNTHETIC PROCESS FOR MANUFACTURE THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-04-05 | — | — | WO | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| EP-2295402-A2 | Antibacterial agents | The University of Washington (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1618087-A4 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
| EP-1618087-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | BCAT2 562/4885KEAP1 1989/4885NFE2L2 1179/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | BCAT2 562/4885KEAP1 1989/4885NFE2L2 1179/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | BCAT2 562/4885KEAP1 1989/4885NFE2L2 1179/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | BCAT2 562/4885KEAP1 1989/4885NFE2L2 1179/4885 |
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | BCAT2 562/4885KEAP1 1989/4885NFE2L2 1179/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | BCAT2 562/4885KEAP1 1989/4885NFE2L2 1179/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | BCAT2 562/4885KEAP1 1989/4885NFE2L2 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.